Prevalence and risk factors of non-alcoholic fatty liver disease in Bangladesh

Shahinul Alam,* Shah Mohammad Fahim,† Muhammad Abdul Baker Chowdhury,‡ Md. Zakiul Hassan,§ Golam Azam,¶ Golam Mustafa, Mainul Ahsan‖ and Nooruddin Ahmad*†

Departments of *Hepatology, †Radiology and Imaging, Bangabandhu Sheikh Mujib Medical University, ‡Nutrition and Clinical Services Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), §Programme for Emerging Infections, Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), ¶Department of Gastrointestinal Hepatobiliary and Pancreatic disorders (GHPD), BIRDEM, Dhaka, and ‖Department of Emergency Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Key words
Bangladesh, fatty liver, non-alcoholic fatty liver disease, obesity, ultrasonography.

Accepted for publication 31 January 2018.

Correspondence
Dr Shahinul Alam, Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka 1000, Bangladesh. Email: shahinul67@yahoo.com

Declaration of conflict of interest: None.

Financial support: None.

Funding support: Incepta Pharmaceuticals Ltd

Abstract
Background and Aim: Non-alcoholic fatty liver disease (NAFLD) is a significant cause of hepatic dysfunction and liver-related mortality. As there is a lack of population-based prevalence data in a representative sample of general population, we aimed to estimate the prevalence and risk factors of NAFLD in Bangladesh.

Methods: A cross-sectional study was conducted both in urban and rural areas of Bangladesh from December 2015 to January 2017. Data were collected using a pre-tested structured questionnaire followed by ultrasonography of hepatobiliary system for screening of NAFLD. Multivariate logistic regression was used to estimate the risk factors of NAFLD.

Results: A total of 2782 (1694 men and 1088 women) participants were included in the study, with a mean age of 34.21 (±12.66) years. The overall prevalence of NAFLD was 33.86% (95% confidence interval [CI]: 32.12, 35.64). Females living in the rural areas and midlife adults (45–54 years) had the highest prevalence of NAFLD (P < 0.05). Multivariable logistic regression model demonstrated that increasing age, diabetes, elevated body mass index, and married individuals are significantly associated with NAFLD. Individuals with diabetes (adjusted odds ratio: 2.71, 95% CI: 1.85, 3.97) and hypertension were at a higher risk of having NAFLD. The odds of having NAFLD were 4.51 (95% CI: 3.47, 5.86) and 10.71 (95% CI: 7.80, 14.70) times higher among overweight and obese participants, respectively, as compared to normal-weight participants.

Conclusions: About one-third of the population of Bangladesh is affected by NAFLD. Individuals with higher body mass index (overweight and obese), diabetics, midlife adults, married individuals, and rural women were more at risk of having NAFLD than others.

Introduction
Non-alcoholic fatty liver disease (NAFLD) ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis.1,2 It is a significant cause of liver-related mortality, associated with severe insulin resistance and increased risk of cardiovascular diseases.3–5 A large proportion of individuals with type 2 diabetes mellitus and a metabolic syndrome develop NAFLD.6,7 and it may also progress to malignancy.3,8 Currently, NAFLD is the most common cause of hepatic dysfunction in developed countries and is predicted to be the same for developing countries within the next few decades.9,10 The prevalence of NAFLD ranges from 20% to 30% in Western countries.9,11 Prevalence in the Middle East, Japan, and China is almost the same as the Western world, with a prevalence rate of 15–30%. In Asian countries, the prevalence of NAFLD varies in different regions. However, in the Indian subcontinent, prevalence of NAFLD is recorded to be 16–32% in urban population and approximately 9–16% in rural areas.9,11,12

Bangladesh is also experiencing an increasing trend of NAFLD due to changing dietary patterns and sedentary lifestyles.13–15 The World Health Organization (WHO) has been documented in May 2014 stating that 2.82% of total deaths in Bangladesh are due to liver diseases. It is the eighth most common cause of death in Bangladesh, and the age-adjusted death rate is 19.26 per 100 000 populations.13–16 Chronic liver diseases (CLDs) are responsible for 37–69% of liver diseases in Bangladesh, and NAFLD is a significant contributor to the burden of chronic liver diseases.15 However, data on the burden of NAFLD are very limited in Bangladesh. The few studies that have been conducted included hospitalized patients,7,11 and little information is available on the community-based estimation of NAFLD burden. In low-income countries like Bangladesh,
hospital-based prevalence estimates may underestimate the true burden of disease as many patients with NAFLD may never seek medical care as a result of being asymptomatic, having limited access to healthcare services, and being in fear of significant economic burden. Population-based prevalence data may help better define the risk groups and provide evidence that can be used to develop effective intervention strategies for the control and prevention of NAFLD. Identification of potential risk factors may lead to the earlier detection of the burden and may help deal with it effectively. Because the implications of NAFLD for health care are substantial, we sought to measure the prevalence and identify the associated risk factors of NAFLD in the general adult population in Bangladesh. This article provides the most recent population-based prevalence and risk estimates of NAFLD and provides an overview of the evidence of the strength of these risk factors.

Methods

Study design and sample. A cross-sectional study was conducted between December 2015 and January 2017 in Dhaka City, the capital of Bangladesh, along with four district towns and four subdistrict towns (small administrative unit) in Bangladesh. The locations were selected purposively. A multi-stage sampling method was followed in order to represent the general population of Bangladesh irrespective of urban and rural areas. Of the 11 city corporations, Dhaka City was selected. The district and subdistrict towns were selected from the larger four divisions of the country. The district towns of Feni, Mymensingh, Bogra, and Patuakhali are located in urban areas, and the subdistrict areas of Pabna sadar upazilla, Chatkhil, Bheramara, and Keraniganj represent the rural areas. The study population comprises healthy individuals who were informed of a free medical camp through an extensive media campaign and through text messages, leaflets, banners, posters, and hand-mike announcing. Participants who attended the medical camp and provided informed consent to participate were enrolled in the study. Higher education group was defined as participants who attained a bachelor degree or above, and those who had a monthly income of more than BDT (Bangladeshi Taka) 15 000 were considered higher income participants.

Data collection. Informed written consent was obtained from each individual participant, and data were collected using a pretested questionnaire through interview followed by physical examination and screening tests for hepatitis B and hepatitis C. A trained physician collected data and performed the physical examination. The questionnaire included demographic characteristics such as age; gender; family history of liver disease; any current medication that may elicit liver disease; medical history; anthropometric measurement; and other comorbid conditions like diabetes (Random Blood Sugar (RBS) >11.1 mmol/L or known case of diabetes), hypertension (known case of hypertension and receiving treatment), previous history of surgery, and previous dental procedure. Any previously diagnosed cases of liver disease were excluded from the study.

Physical examination and biochemical tests. Physical examination was performed by physicians to detect any signs of jaundice, abdominal mass, or any other symptoms related to liver diseases. Screening tests for the serum markers of hepatitis B (HBsAg) and hepatitis C (anti-HCV) viruses were also carried out using the rapid strip test. Height was measured by standard stadiometer, and weight was measured using a standard bathroom scale. Anthropometric measurements were cross checked to ensure the interrater reliability. Body mass index (BMI) was calculated using height in cm and weight in kg. We used a WHO-approved BMI scale for Asian populations: underweight (<18.5 kg/m²), normal weight (18.5 to <23.0 kg/m²), overweight (23.0 to <27.5 kg/m²), and obese (≥27.50 kg/m²).

Detection of fatty liver. Ultrasonography (USG) of the hepatobiliary system was used to diagnose the presence or absence of NAFLD. USG is considered an easily available, cost-effective, and essentially noninvasive method for the detection of NAFLD. A postgraduate-trained sonographer performed USG of the hepatobiliary system for each subject. The physicians scanned the liver, biliary tract, spleen, and the kidney using a sonographic machine equipped with 3.5 MHz transducers. Fatty liver was diagnosed by the sonographic findings of the echogenicity of the liver, which is greater than that of the renal cortex; intrahepatic vessels are not well depicted; the ultrasound beam is attenuated posteriorly; and the diaphragm is poorly delineated. As cirrhotic liver may also present bright echogenicity, it was excluded by medical history, physical examinations, and sonographic findings like the coarse echo texture of liver.

Statistical analysis. We summarized the data using frequency and percentages. We used multivariable logistic regression to identify covariates of NAFLD. An arbitrary P-value of <0.20 was used as a criterion to include the variables in the multivariable logistic regression model to control for confounding effects, and the results were considered statistically significant at a P-value of ≤0.05. Using the logistic regression procedure, we estimated the odds ratio (OR) and 95% confidence interval (CI) for each covariate to identify risk factors of NAFLD. We considered forward, backward, and stepwise model selection procedures in the analysis. To select the best model, the values of −2Log Likelihood ratio test, the Akaike information criterion (AIC), and the area under the receiver operating characteristic (ROC) curve were examined. The lower values of −2Log Likelihood ratio test and AIC represent the better model. Before entering the independent variables into the multivariable models, we checked the variation inflation factor (VIF) to avoid the problem of multicollinearity. All statistical procedures were performed using the StataMP software (Version 13.0; StataCorp, College Station, TX, USA).

Results

The distribution of sociodemographic, anthropometric, and clinical characteristics of the study participants is presented in Table 1 according to whether they had NAFLD. A total of 2782 (1694 men and 1088 women) participants were included in the study. Mean age was 34.21 years (±12.66), ranging from 18 to 85 years. Among the participants, 1694 (60.86%) were male, 2118 (76.13%) were from urban areas, and one-fourth (713) of
the study participants had higher education. The mean BMI, Systolic Blood Pressure (SBP), and Diastolic Blood Pressure (DBP) of the study participants were 23.82 kg/m² (±4.43), 115.13 mmHg (±9.93), and 70.62 mmHg (±7.4), respectively.

Prevalence of NAFLD. The prevalence of NAFLD is presented in Table 2 according to the characteristics of the individuals in the study population and their demographic and clinical covariates. The overall prevalence of NAFLD in the study population was 33.86% (95% CI: 32.12 – 35.64), and there was no significant difference between the genders (P = 0.961). Individuals from rural areas had a higher prevalence—36.95% (95% CI: 33.01 – 40.33)—of NAFLD than the individuals from urban areas—33.00% (95% CI: 31.03 – 39.93). High-income individuals had more than 1.5 times higher prevalence (50.38%, 95% CI: 46.52 – 54.24) of NAFLD than low-income individuals (31.14%, 95% CI: 23.53 – 39.93). Interestingly, the prevalence rate of NAFLD was similar among the respondents irrespective of educational attainment. The prevalence ranged between 29% and 36%. NAFLD prevalence was 71.18%, 62.8%, and 40.77% among diabetic, hypertensive, and individuals with family history of liver disease, respectively. Respondents with high BMI (overweight and obesity) have a higher prevalence of NAFLD.

The prevalence of NAFLD by age group and place of residence is presented in Figure 1. We observed that the prevalence of NAFLD increases with increase of age. With the exception of the 35–44 years age group, rural individuals from all other (younger and older) age groups had a higher prevalence of NAFLD than urban individuals. Rural study participants aged 45–54 years had the highest prevalence (58.43%) followed by

---

| Characteristic                        | No NAFLD     | NAFLD        | Total        | P-value† |
|---------------------------------------|--------------|--------------|--------------|----------|
| Age (years), mean (SD)                | 31.38 (12.19)| 39.73 (11.71)| 34.21 (12.66)| <0.0001  |
| Gender, n (%)                         |              |              |              | 0.961    |
| Male                                  | 1121 (66.2)  | 573 (33.8)   | 1694 (100)   |          |
| Female                                | 719 (66.1)   | 369 (33.9)   | 1088 (100)   |          |
| Place of residence, n (%)             |              |              |              | 0.088    |
| Urban                                 | 1419 (77.12)| 699 (74.2)   | 2118 (76.13) |          |
| Rural                                 | 421 (22.88) | 243 (25.8)   | 664 (23.87)  |          |
| Marital status, n (%)                 |              |              |              | <0.0001  |
| Married                               | 1159 (62.99)| 743 (89.49)  | 2002 (71.96) |          |
| Not married                           | 681 (37.01) | 99 (10.51)   | 780 (28.04)  |          |
| Income, n (%)                         |              |              |              |          |
| Low                                   | 84 (8.39)    | 38 (6.5)     | 122 (7.69)   | <0.0001  |
| Medium                                | 597 (59.64)  | 222 (37.95)  | 819 (51.64)  |          |
| High                                  | 320 (31.97)  | 325 (55.56)  | 645 (40.67)  |          |
| Education, n (%)                      |              |              |              | 0.152    |
| No education                          | 221 (12.01)  | 121 (12.85)  | 342 (12.29)  |          |
| Primary                               | 500 (27.17)  | 246 (26.11)  | 746 (26.82)  |          |
| Secondary                             | 331 (17.99)  | 178 (18.9)   | 509 (18.3)   |          |
| Higher secondary                      | 333 (18.1)   | 139 (14.76)  | 472 (16.97)  |          |
| Higher                                | 455 (24.73)  | 258 (27.39)  | 713 (25.63)  |          |
| BMI, mean (SD)                        | 22.48 (3.93) | 26.61 (4.07) | 23.87 (4.43) | <0.0001  |
| SBP (mmHg) (mean, SD)                 | 113.18 (9.5) | 118.94 (9.66)| 115.13 (9.93)| <0.0001  |
| DBP (mmHg) (mean, SD)                 | 69.53 (7.31) | 72.76 (7.11) | 70.62 (7.4)  | <0.0001  |
| Hypertension, n (%)                   |              |              |              | <0.0001  |
| Yes                                   | 61 (4.54)    | 103 (13.29)  | 164 (7.74)   |          |
| No                                    | 1282 (95.46) | 672 (86.71)  | 1954 (92.26) |          |
| Diabetes, n (%)                       |              |              |              | <0.0001  |
| Yes                                   | 51 (3.79)    | 126 (16.26)  | 177 (8.35)   |          |
| No                                    | 1294 (96.21) | 649 (83.74)  | 1943 (91.65) |          |
| Blood transfusion                     |              |              |              | 0.002    |
| Yes                                   | 79 (5.88)    | 74 (9.57)    | 153 (7.23)   |          |
| No                                    | 1265 (94.12) | 699 (90.43)  | 1964 (92.77) |          |
| Hepatitis B, n (%)                    |              |              |              | 0.575    |
| Positive                              | 97 (5.27)    | 45 (4.78)    | 142 (5.1)    |          |
| Negative                              | 1743 (94.73)| 897 (95.22)  | 2640 (94.9)  |          |
| Family history of liver disease       |              |              |              | 0.006    |
| Yes                                   | 183 (9.95)   | 126 (13.38)  | 309 (11.1)   |          |
| No                                    | 1657 (90.05)| 816 (86.62)  | 2473 (88.89) |          |

†P-values were calculated using the Student’s t-test or chi-square test.
‡Data are presented as mean (SD) or number (%) for continuous and categorical variables.
BMI, body mass index; DBP, Diastolic Blood Pressure; NAFLD, non-alcoholic fatty liver disease; SBP, Systolic Blood Pressure.
The prevalence that we have estimated in this study is higher than that of neighboring countries and the previous reports from Bangladesh. This is in accordance with the increasing trend of fatty liver globally and also strengthens the existing evidence of increasing NAFLD prevalence in this region. However, the neighboring state of West Bengal in India has demonstrated a prevalence to be about 8%–9% in a previous study, despite having a similar sociocultural background. Our study explored a higher prevalence of NAFLD that could be explained by the percentage is very low (5.42%). NAFLD was observed among 14.47% subjects with normal BMI. Similar to the finding regarding age groups, rural women had a higher prevalence of NAFLD than any other BMI categories. We observed the highest prevalence (73.21%) among rural obese women than any other BMI classifications (Table S1).

### Risk factors

The individuals with NAFLD had significantly higher BMI, SBP, and DBP ($P < 0.001$). Individuals with NAFLD were more likely to have hypertension and diabetes, had a previous blood transfusion, and had a family history of liver disease. Study participants with higher income (55.56% vs 31.97%) and higher education (27.39% vs 24.73%) had a higher likelihood of having NAFLD; however, the level of education was not significant for NAFLD and non-NAFLD groups.

Table 3 shows the risk factors associated with NAFLD from the multivariable logistic regression analysis, with adjusted ORs (AORs) and 95% CIs. Study participants with increasing age, with diabetes and higher BMI (overweight and obesity), and who were married were more likely to have NAFLD. The risk of NAFLD was significantly higher among individuals aged 35–44 years (AOR = 3.00, 95% CI: 1.94–4.63) and those aged 45–54 years (AOR = 4.14, 95% CI: 2.63 – 6.53) compared to individuals younger than 24 years. For individuals with diabetes, the odds of having NAFLD were 2.71 (95% CI: 1.85 – 3.97) times higher than the individuals without diabetes. The odds of having NAFLD was 4.51 (95% CI: 3.47 – 5.86) and 10.71 (95% CI: 7.80 – 14.70) times higher among overweight and obese study participants, respectively, as compared to normal-weight study participants. The analysis also indicated that individuals who were underweight were less prone (AOR = 0.48, 95% CI: 0.27 – 0.85) to have NAFLD compared to normal-weight study participants. In addition, married study participants had a 67% (AOR: 1.67, 95% CI: 1.17 – 2.37) higher chance of having NAFLD as compared to the study participants who were not married. In this study, we used Hosmer and Lemeshow’s (H–L) goodness-of-fit test and area under the curve (AUC) using ROC curve to assess our final model. The Hosmer and Lemeshow statistic had a significance of 0.6102, meaning that it was not statistically significant, and therefore, our model is a good fit. In addition, the area under curve of the ROC was found to be 0.82 (Fig. S1), which also indicates a very good prediction of the outcome.

### Discussion

Our study results demonstrated that one in every three individuals in Bangladesh had NAFLD. This result delineates the serious epidemic of NAFLD in the country and highlights the further risk of increasing liver-related morbidity and mortality. The prevalence that we have estimated in this study is higher than that of neighboring countries and the previous reports from Bangladesh. This is in accordance with the increasing trend of fatty liver globally and also strengthens the existing evidence of increasing NAFLD prevalence in this region. However, the neighboring state of West Bengal in India has demonstrated a prevalence to be about 8%–9% in a previous study, despite having a similar sociocultural background. Our study explored a higher prevalence of NAFLD that could be explained by the

### Table 2 Prevalence of NAFLD among adults in Bangladesh by characteristics, Bangladesh 2017

| Characteristic          | NAFLD prevalence, % (95% CI) |
|-------------------------|------------------------------|
| Gender                  |                              |
| Male                    | 33.82 (31.6 – 36.11)         |
| Female                  | 33.91 (31.15 – 36.78)        |
| Age group               |                              |
| <24                     | 9.25 (7.33 – 11.61)          |
| 25–34                   | 30.91 (27.95 – 34.04)        |
| 35–44                   | 48.72 (44.56 – 52.9)         |
| 45–54                   | 55.38 (50.4 – 60.25)         |
| 55+                     | 48.37 (42.17 – 54.62)        |
| Place of residence      |                              |
| Urban                   | 33.00 (31.03 – 35.03)        |
| Rural                   | 36.59 (33.01 – 40.33)        |
| Income                  |                              |
| Low                     | 31.14 (23.53 – 39.93)        |
| Medium                  | 27.11 (24.16 – 30.25)        |
| High                    | 50.38 (46.52 – 54.24)        |
| Education               |                              |
| No education            | 35.38 (30.48 – 40.6)         |
| Primary                 | 32.97 (29.69 – 36.43)        |
| Secondary               | 34.97 (30.94 – 39.22)        |
| Higher secondary        | 29.44 (25.5 – 33.72)         |
| Higher                  | 36.18 (32.73 – 39.78)        |
| Hypertension            |                              |
| Yes                     | 62.8 (55.13 – 69.88)         |
| No                      | 34.39 (32.31 – 36.52)        |
| Diabetes                |                              |
| Yes                     | 71.18 (64.06 – 77.39)        |
| No                      | 33.4 (31.33 – 35.53)         |
| Blood transfusion       |                              |
| Yes                     | 48.36 (40.52 – 56.28)        |
| No                      | 35.59 (33.35 – 37.73)        |
| Hepatitis B             |                              |
| Positive                | 31.69 (24.54 – 39.81)        |
| Negative                | 33.97 (32.19 – 35.8)         |
| Family history of liver disease |                  |
| Yes                     | 40.77 (35.42 – 46.36)        |
| No                      | 32.99 (31.16 – 34.87)        |
| BMI                     |                              |
| Underweight             | 5.42 (3.34 – 8.67)           |
| Normal                  | 14.47 (12.34 – 16.88)        |
| Overweight              | 44.05 (41.03 – 47.11)        |
| Obese                   | 63.55 (59.37 – 67.52)        |

BMI, body mass index; CI, confidence interval; NAFLD, non-alcoholic fatty liver disease.
global trend of higher prevalence, increasing awareness for sono-
graphic detection for NAFLD, recent economic growth with life-
style change, and the religious conservative attitude of rural
Bangladeshi women.

Several risk factors for NAFLD have been identified in
this study. Individuals with NAFLD were more likely to have
hypertension, diabetes, previous blood transfusion, higher
income, be married, and have family history of liver disease. We
found that increasing age is a strong and independent risk factor
for NAFLD. NAFLD is perceived to be a disease that mainly
affects the middle and older age group.33 But, in our population,
an age older than 24 years was an independent predictor of hav-
ing fatty liver. Prevalence among the 25–34 years age group was
30.91% (95% CI: 27.95 – 34.04), which increases with age.
Studies have shown that fatty changes in liver increase with
age.34 We have observed the same trend of amplified prevalence

![Figure 1](https://example.com/figure1.png)

**Figure 1** Prevalence of non-alcoholic fatty liver disease by age group and place of residence. □ Urban; ■ rural; III overall.

![Figure 2](https://example.com/figure2.png)

**Figure 2** Prevalence of non-alcoholic fatty liver disease by body mass index category and place of residence. Blue, Urban; Red, rural; Black, overall.
with increasing age. Young people aged less than 24 years were much less affected, and the risk increases in each decade of life from 25 to 54 years. Midlife adults aged between 45 and 54 years demonstrated the highest prevalence (55.38%), and the risk decreased among individuals older than 55 years. Previous studies have documented that the average age for NASH is 40–50 years. Prevalence of NAFLD is highest among adults aged 40–60 years in India, and liver-related mortality is the fourth leading cause of death among adults aged 45–54 years in USA. Our findings are also in accordance with those demonstrating that the highest prevalence occurs in adults of 45–54 years. However, this is contrary to the findings of many studies which demonstrated that older individuals are more vulnerable of developing fatty liver disease and its associated complications. However, in our series, prevalence was found to be lower (12.63%) among elderly individuals.

Findings from previous studies confirmed that NAFLD has a profound association with diabetes mellitus and higher BMI (overweight and obesity). NAFLD is known as the hepatic component of metabolic syndrome, and stronger evidence demonstrates its association with diabetes mellitus. We have found diabetes to be an independent predictor of having NAFLD (OR: 2.71, 95% CI: 1.85–3.97, P < 0.0001). In our study, 71.18% of NAFLD cases were observed in subjects with diabetes. This finding confirmed the strong association of diabetes with fatty changes in liver, showing accordance with the previous studies.

Patients with NAFLD are typically found to be overweight or obese. Our data suggested that subjects with NAFLD are more likely to be overweight and obese, confirming that BMI is an independent predictor of NAFLD. Mean BMI of the participants recruited in our study was 23.87 kg/m², but the participants with NAFLD had a much higher mean BMI (26.61 kg/m²). Obese individuals had more than four times higher prevalence (14.47% vs 63.55%) than normal-weight individuals. Logistic regression model showed that ORs for obese groups were significantly higher (OR: 10.71, 95% CI: 7.80–14.70, P < 0.0001), indicating obesity to be an independent risk factor for NAFLD. Being overweight is also a significant factor associated with NAFLD. The odds of developing a fatty liver among overweight subjects were 4.51 times higher than normal individuals. Because it was evident that fatty liver is predominant among subjects with elevated BMI, it was believed that overweight subjects are not affected by NAFLD, but our study result revealed that overweight subjects also developed NAFLD, although the percentage is very low (5.42%). NAFLD was even observed among 14.47% subjects with normal BMI. There is emerging but limited evidence that NAFLD may affect lean or normal individuals, especially Asians. In Asian countries, such as South Korea, Japan, and India, the prevalence of NAFLD among lean individuals ranges from 12% to 20%, and our findings are also in accordance with this.

Furthermore, the study results indicated that NAFLD prevalence was 62.8% among hypertensive subjects, although it was not found to be an independent predictor in multivariable analysis. We have identified that women living in the rural areas are at a greater risk of developing NAFLD. Data from various studies suggested that men have a higher predilection for developing NAFLD than women. In our study, overall, both males and females were equally affected (P = 0.961) by the fatty changes in liver. However, in rural areas, women were almost 10% more (1.27 times more) prone to developing NAFLD than men. Several hospital-based studies from Bangladesh reported female preponderance of fatty liver in the country. In rural areas, women usually stay at home due to social conservativeness, which causes them to lead a sedentary lifestyle. This might be a cause of female preponderance of NAFLD in rural areas.

Among the three grades of NAFLD, the prevalence of Grade I (26.10%) was higher in Bangladesh. Although this condition is benign, there may be significant changes in liver, to NASH or cirrhosis, if Grade I progresses to further stages. Finally, it was demonstrated in the present study that married individuals are at greater risk of developing NAFLD. ORs were found to be significantly higher among those who were married (OR: 1.67, 95% CI: 1.17–2.37, P < 0.0001), but there is no evidence supporting this finding, and that is why we could not elucidate any justification. It could be explained as follows: in south Asian populations, marriage is usually associated with ‘settling down in life’, having a job, and having a living with a regular source of income. The cultural practice in south Asians is usually to get married when they have a regular source of income, and this may be one reason for a lifestyle where they have access to excess calorie intake and lower physical activity, leading to a higher prevalence in married individuals. Blood transfusion was not associated with HCV infection in this series. So, it could not explain the association of NAFLD with blood transfusion.

The strength of this study includes the large sample size, which included both the urban and rural population of Bangladesh. Our study has several limitations as well. We have diagnosed NAFLD on the basis of ultrasonographic findings, which were not confirmed by liver biopsy, the gold standard for diagnosing NAFLD. However, USG is noninvasive and is certainly the most common method for diagnosing NAFLD in clinical practice. It has very high sensitivity and specificity for detecting hepatic steatosis, which may vary from 60% to 94%

Table 3 Logistic regression model for fatty liver disease in Bangladesh, 2017

| Age groups | OR   | 95% CI          | P-value |
|------------|------|-----------------|---------|
| ≤24        | Reference |                |         |
| 25–34      | 2.00 | 1.35–2.94       | <0.0001 |
| 35–44      | 3.00 | 1.94–4.63       | <0.0001 |
| 45–54      | 4.14 | 2.63–6.53       | <0.0001 |
| 55+        | 3.77 | 2.29–6.21       | <0.0001 |

| Marital status | OR   | 95% CI          | P-value |
|----------------|------|-----------------|---------|
| Not married    | Reference |                |         |
| Married        | 1.67 | 1.17–2.37       | 0.004   |

| Diabetes | OR   | 95% CI          | P-value |
|----------|------|-----------------|---------|
| No       | Reference |                |         |
| Yes      | 2.71 | 1.85–3.97       | <0.0001 |

| BMI       | OR   | 95% CI          | P-value |
|-----------|------|-----------------|---------|
| Underweight | 0.48 | 0.27–0.85       | 0.012   |
| Normal    | Reference |                |         |
| Overweight | 4.51 | 3.47–5.86       | <0.0001 |
| Obese     | 10.71 | 7.80–14.70      | <0.0001 |

BMI, body mass index; CI, confidence interval; OR, odds ratio.
and 88% to 95%, respectively. Several studies have suggested that, due to the obvious sensitivity and specificity of simple ultrasound, liver biopsy is hardly ever required to diagnose NAFLD.47,48

In conclusion, the results of this study demonstrate that about one-third population of Bangladesh is affected by NAFLD, and the prevalence is higher than neighboring countries, putting the population at an increased risk of liver-related morbidity and mortality. Early to midlife adults; diabetic, overweight, and obese individuals; rural women; and married individuals are at a greater risk of developing NAFLD than others. Young and nonobese individuals are not also spared by NAFLD. Modifiable risk factors identified in this study might help to develop feasible interventions for the early detection and management of NAFLD. In addition, it will lead to the development and implementation of national programs to prevent NAFLD and control its associated risk factors.

Acknowledgment

This study was funded by Incepta Pharmaceuticals Ltd.

References

1. Walker BR, Colledge NR. Davidson’s Principles and Practice of Medicine. Elsevier Health Sciences, Edinburgh, Scotland, 2013.
2. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116: 1413–19.
3. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J. Hepatol. 2008; 49: 608–12.
4. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Forum Nutr. 2013; 5: 1544–60.
5. Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014; 59: 713–23.
6. Duseja A, Chalasani N. Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD). Hepatol. Int. 2013; 7: 755–64.
7. Souza MR, Diniz MD, Medeiros-Filho JE, Araújo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arg. Gastroenterol. 2012; 49: 89–96.
8. Michieliotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 2013; 10: 656–65.
9. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 2013; 10: 686–90.
10. Ray K. NAFLD—the next global epidemic. Nat. Rev. Gastroenterol. Hepatol. 2013; 10: 621.
11. Rahman MM, Kibria GM, Begum H et al. Prevalence and risk factors of nonalcoholic fatty liver disease in a rural community of South Asia. Gastroenterology. 2015; 148: S1045–6.
12. Das K, Das K, Mukherjee PS et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010; 51: 1593–602.
13. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013; 380: 2095–128.
14. Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J. Gastrointest. Pathophysiol. 2016; 7: 211–17.
15. Rahman S, Ahmed MF, Alam MJ et al. Distribution of liver disease in Bangladesh: a cross-country study. Eurasian J. Hepatogastroenterol. 2014; 4: 25–30.
16. World Health Organization. Bangladesh Health Profile. World Health Organization, Geneva, Switzerland, 2014.
17. Alam S, Noor-E-Alam SM, Chowdhury ZR, Alam M, Kabir J. Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh. World J. Hepatol. 2013; 5: 281–7.
18. Alam S, Gupta UD, Alam M, Kabir J, Chowdhury ZR, Alam AK. Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh. Indian J. Gastroenterol. 2014; 33: 452–7.
19. Rahim ZB, Rahman MM, Saha D, Hosen SZ, Paul S, Kader S. Ethnomedical plants used against jaundice in Bangladesh and its economical prospects. Bull. Pharm. Res. 2012; 2: 91–105.
20. Hossain MZ, Sikder SS, Zaman K et al. Screening utility, local perceptions, and care-seeking for reported jaundices among respondents lacking signs of icterus in rural Bangladesh. J. Health Popul. Nutr. 2013; 31: 367.
21. El Khoury AC, Wallace C, Klimack WK, Razavi H. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J. Med. Econ. 2012; 15: 887–96.
22. Lu J, Xu A, Wang J et al. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. BMC Health Serv. Res. 2013; 13: 37.
23. Dassanyake AS, Kasturiratne A, Rajindrajith S et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J. Gastroenterol. Hepatol. 2009; 24: 1284–8.
24. Steering Committee. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Melbourne: International Diabetes Institute, 2000.
25. Barba C, Cavalli-Sforza T, Cutter J, Darmon-Hill I. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363: 157.
26. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Shunichi T. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn. J. Med. 1988; 27: 142–9.
27. Khov N, Sharma A, Riley TR. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J. Gastroenterol. 2014; 20: 6821–5.
28. Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J. Gastroenterol. 2014; 20: 7392–402.
29. Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of non-alcoholic fatty liver disease (NAFLD). Ann. J. Gastroenterol. 2007; 102: 2716–17.
30. Harbin WP, Robert NJ, Ferrucci JT Jr. Diagnosis of cirrhosis based on regional changes in hepatic morphology: a radiological and pathological analysis. Radiology. 1980; 135: 273–83.
31. Sandford NL, Walsh P, Matis C, Baddeley H, Powell LW. Is ultrasonography useful in the assessment of diffuse parenchymal liver disease? Gastroenterology. 1985; 89: 186–91.
32. Debongnie JC, Pauls C, Fievez M, Wibin E. Prospective evaluation of the diagnostic accuracy of liver ultrasonography. Gut. 1981; 22: 130–5.
33. Amarapurkar D, Kamani P, Patel N et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann. Hepatol. 2007; 6: 161–3.
34. Lazo M, Hernaez R, Eberhardt MS et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am. J. Epidemiol. 2013; 178: 38–45.
35 Frith J, Day CP, Henderson E, Burt AD, Newton JL. Non-alcoholic fatty liver disease in older people. Gerontology. 2009; 55: 607–13.
36 Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 346: 1221–31.
37 Angelico F, Del Ben M, Conti R et al. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J. Gastroenterol. Hepatol. 2003; 18: 588–94.
38 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013; 10: 330–44.
39 Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study. Hepatology. 2005; 42: 44–52.
40 Ekstedt M, Franzén LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44: 865–73.
41 Wang S, Zhang H, Tong B et al. Body mass index is a risk factor for new-onset non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Zhonghua Gan Zang Bing Za Zhi. 2015; 23: 754–9.
42 Wattacheril J, Sanyal AJ. Lean NAFLD: an underrecognized outlier. Curr. Hepatol. Rep. 2016; 15: 134–9.
43 Park SH, Jeon WK, Kim SH et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J. Gastroenterol. Hepatol. 2006; 21: 138–43.
44 Agarwal AK, Jain V, Singla S et al. Prevalence of non-alcoholic fatty liver disease and its correlation with coronary risk factors in patients with type 2 diabetes. J. Assoc. Physicians India. 2011; 59: 351–4.
45 Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001; 121: 91–100.
46 Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur. J. Gastroenterol. Hepatol. 2003; 15: 539–43.
47 Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 2006; 40: S34–8.
48 Caturelli E, Rapaccini GL, Sabelli C et al. Ultrasonography and echo-guided fine-needle biopsy in the diagnosis of focal fatty liver change. Hepatogastroenterology. 1987; 34: 137–40.

Supporting information
Additional supporting information may be found in the online version of this article at the publisher’s website:

Table S1. Prevalence of non-alcoholic fatty liver disease by gender and place of residence, Bangladesh 2017.

Figure S1. Receiver operating characteristic curve.